<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075526</url>
  </required_header>
  <id_info>
    <org_study_id>19-00851</org_study_id>
    <nct_id>NCT04075526</nct_id>
  </id_info>
  <brief_title>Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty</brief_title>
  <official_title>Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, controlled, open label, parallel four-arm design,
      multi-center study to compare different intraoperative interventions in the prevention of
      acute PJI development.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study seeks to define the potential benefits that an additional prophylactic protocol
      involving the use of povidone iodine and vancomycin powder on the incidence of PJI in high
      risk TJA patients. The potential benefits of these interventions are significant both from
      the perspective of reducing morbidity and mortality for the patient, and from a
      cost-effectiveness and value-based perspective. To this end, our study seeks to assess the
      direct and indirect costs associated with the treatment and control groups. We anticipate
      that the administration of a VPIP protocol will both reduce the incidence of PJI in high risk
      groups relative to the control arm and will demonstrate added value from a cost-effectiveness
      perspective.

      This study looks to examine off-label use of Vancomycin Powder and Povidone Iodine 10%
      solution. Both products are lawfully marketed in the United States. This study is not
      intended to be reported to the FDA as a well-controlled study in support of a new indication
      and there is no intent to use it to support any other significant change in the labeling or
      advertising of either drug.

      This study does not involve a route of administration, dose, patient population, or other
      factor that significantly increased the risk (or decreases the acceptability of the risk)
      associated with the use of the drug product. The routes and dosages being tested in this
      protocol are part of standard clinical care in most total joint arthroplasty surgeries.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of periprosthetic infection (PJI) after elective total joint arthroplasty.</measure>
    <time_frame>90 Days</time_frame>
    <description>The definition of periprosthetic infection exists when the following criteria are met:
NEW MSIS criteria for PJI: 1 major criteria (2) or 6 minor criteria (6) 26-28
Major Criteria: [1] sinus tract [2] + Cx from 2 separate aspirations
Minor Criteria: [1] ESR &gt;30 mm/hr (1 point), [2] D-dimer &gt;860 ng/mL or CRP &gt;1 mg/dL [2] increased synovial WBC (&gt;3000 cells/microliter) [4] alpha-defensin (signal-to-cutoff ratio&gt;1) [5] leukocyte esterase (++) [6] increased synovial PMNs of &gt;80% [7] synovial CRP &gt;6.9 mg/L</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Povidone iodine and vancomycin powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Povidone iodine alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin powder alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>neither povidone iodine, vancomycin powder, nor polymyxin/bacitracin irrigation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone iodine</intervention_name>
    <description>To create the dilute solution, a staff member will draw up 17.5 mL of 10% povidone iodine with a syringe and mix it with 500 mL of normal saline, resulting in a dilution of 0.35% povidone iodine solution for use before wound closure.</description>
    <arm_group_label>Povidone iodine alone</arm_group_label>
    <arm_group_label>Povidone iodine and vancomycin powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin powder</intervention_name>
    <description>2 grams of vancomycin powder will be applied to the wound and will be distributed so that approximately 1 gram is administered deep to the fascia and 1 gram superficial to the fascia</description>
    <arm_group_label>Povidone iodine and vancomycin powder</arm_group_label>
    <arm_group_label>Vancomycin powder alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional</intervention_name>
    <description>No additional steps in management are required for the control arm of the study besides lavage with 1 L of isotonic sodium chloride solution without antibiotics. No vancomycin powder or dilute povidone iodine lavage would be utilized in this cohort</description>
    <arm_group_label>Conventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has no open wounds on operative leg

          -  Patient is scheduled to undergo elective primary and revision total joint arthroplasty
             for posttraumatic, osteoarthritis, avascular necrosis, and/or inflammatory arthritis

          -  Patient does not have active infection on the operative leg, the operative joint

          -  Patient are identified as high risk for the development of PJI which is determined by
             the presence of one or more of the following characteristics: BMI &gt;35, active smoker,
             ASA â‰¥ 3, immunosuppressed (i.e. being treated with chemotherapy, diagnosis of HIV,
             diagnosis of HCV, being treated with chronic steroids, patients with inflammatory
             arthropathies), diagnosis with diabetes mellitus, established colonization with S.
             aureus, or any patient undergoing revision TJA

          -  Patient understand the risks and benefits associated with TJA and willing to cooperate
             and follow study protocol and visit schedule

        Exclusion Criteria:

          -  Patient is pregnant

          -  Patient is unable to provide written consent

          -  Patient has psychiatric disorder that precludes safe study participation or that
             necessitates confinement in a custodial environment at home or in a chronic care
             facility

          -  Patient does not have the mental capacity to participate and comply with the study
             protocol

          -  Patient has active infections in the operative leg/joint

          -  Patient has severe dementia

          -  Suspicion of illicit drug abuse by patient

          -  ASA score of 5 &amp; 6

          -  History of prior native septic joint arthritis

          -  No planned procedure within 90 days of surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Long</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Waren</last_name>
    <phone>212-598-6245</phone>
    <email>Daniel.Waren@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisenhower Health</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Schnaser, MD</last_name>
      <phone>909-558-4729</phone>
    </contact>
    <investigator>
      <last_name>Erik Schnaser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carlos Higuera, MD</last_name>
      <phone>954-659-5000</phone>
      <email>higuerc@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brett Levine, MD</last_name>
      <phone>877-632-6637</phone>
      <email>levine.research@rushortho.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonia Chen</last_name>
      <phone>617-732-5500</phone>
      <email>afchen@bwh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kain, MD</last_name>
      <phone>781-744-5100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Baptist Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Smith, MD</last_name>
      <phone>617-754-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Dept of Orthopeadic Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Long, MD</last_name>
      <phone>646-293-7515</phone>
      <email>William.Long2@nyulangone.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Vigdorchik</last_name>
      <phone>212-606-1992</phone>
      <email>VigdorchikJ@hss.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bill Hamilton, MD</last_name>
      <phone>212-241-6500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Cooper, MD</last_name>
      <phone>212-305-4565</phone>
      <email>hjc2008@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Ohio</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Piuzzi, MD</last_name>
      <phone>216-444-2200</phone>
      <email>piuzzin@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Mount Vernon Hospital</name>
      <address>
        <city>Alexandria</city>
        <state>Virginia</state>
        <zip>22306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sershon, MD</last_name>
      <phone>703-619-4400</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

